Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.20DKK
6:29am EDT
Change (% chg)

kr.0.01 (+0.84%)
Prev Close
kr.1.19
Open
kr.1.19
Day's High
kr.1.21
Day's Low
kr.1.19
Volume
332,023
Avg. Vol
1,858,211
52-wk High
kr.2.10
52-wk Low
kr.0.93

Summary

Name Age Since Current Position

Michael Heffernan

51 2016 Independent Chairman of the Board

Craig Collard

48 2015 President, Chief Executive Officer

Mette Agger

52 2016 Independent Deputy Chairman of the Board

Alastair McEwan

61 2016 Chief Operating Officer, Executive Vice President

Ron Guido

Senior Vice President, Global Regulatory Affairs, Chief Compliance Officer

Breian Knudsen

Vice President, Technical Operations

Anders Goetzsche

48 2008 Independent Director

Robert Radie

52 2016 Independent Director

Lars Viksmoen

67 2016 Independent Director

Paul Wotton

55 2016 Independent Director

Biographies

Name Description

Michael Heffernan

Mr. Michael Thomas Heffernan has been Independent Chairman of the Board of Directors at Veloxis Pharmaceuticals A/S since April 6, 2016. He has previously been Independent Director since March 26, 2015. Mr. Heffernan is Co-Founder, President & CEO of Collegium Pharmaceutical Inc. Prior to this, Mr. Heffernan was Founder, President & CEO of Onset Therapeutics Inc. Before this Mr. Heffernan has also held positions as Co-Founder, President & CEO of Clinical Studies Ltd, and as President & CEO of PhyMatrix Inc. Mr. Heffernan has a B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist. Mr. Heffernan is the chairman of Ocata Therapeutics Inc.

Craig Collard

Mr. Craig A. Collard has been President and Chief Executive Officer at Veloxis Pharmaceuticals A/S since December 10, 2015. Craig A. Collard has more than 20 years’ track record of strategic and tactical leadership within the pharmaceutical industry. In 2003, he founded Cornerstone Therapeutics, Inc. and chaired the company until 2014 where it was sold to Chiesi Farmaceutici SpA.

Mette Agger

Ms. Mette Kirstine Agger has been Independent Deputy Chairman of the Board of Directors of Veloxis Pharmaceuticals A/S since April 6, 2016. She has previously been Independent Chairman of the Board since March 26, 2015. She has been Independent Director of the Company since April 21, 2010. She is Managing Partner at Lundbeckfond Vetures and Member of the Boards of Directors of Klifo A/S, PsiOxis Therapeutics Ltd., Cydan LLC., scPharmaceuticals LLC, Thesan Pharmaceuticals Inc. and Vtesse Pharma. She has international pharmaceutical experience. Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing. Ms. Agger has a Master of Science in Biology from Copenhagen University and MBA from the Henley Business School.

Alastair McEwan

Mr. Alastair S. McEwan has been Chief Operating Officer and Executive Vice President at Veloxis Pharmaceuticals A/S since February 29, 2016. Alastair McEwan has been involved in pharmaceutical development and commercialization for over twenty years. He has broad general management, financial and M & A expertise derived from his past roles including President, Global Clinical at Inveresk Research and CFO of Cornerstone Therapeutics during its expansion and integration of EKR and its subsequent sale to Chiesi Farmaceutici.

Ron Guido

Mr. Ron Guido serves as Senior Vice President, Global Regulatory Affairs and Chief Compliance Officer at Veloxis Pharmaceuticals A/S. Ron Guido has been employed in pharmaceutical development since 1980, in the areas of Preclinical Screening, Clinical Research, Regulatory Affairs, Product Development and Quality Systems. Experience includes development strategy, merger, and acquisition, as well as commercial support for new and marketed products. Past positions include Vice-President Regulatory, Retrophin, Inc, Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer as well as senior roles with V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth Ayerst Laboratories. His undergraduate education is in Biology and Psychology, and he holds a Master of Science in Technical Communications from the Polytechnic University, New York, and a Master of Science in Pharmaceutical Medicine from Hibernia College, Dublin. He is currently Lecturer in Biology in The Masters of Biotechnology Program at Columbia University of the City of New York.

Breian Knudsen

Mr. Breian Knudsen serves as Vice President, Technical Operations at Veloxis Pharmaceuticals A/S. Mr. Knudsen joined the Company in November 2007. He is responsible for technology transfer, process validation, clinical and commercial manufacturing. Mr. Knudsen has experience within process and product development, technology transfer, process validation and manufacture within the pharmaceutical industry. Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes. Mr. Knudsen holds a Master of Science in pharmacy from the Pharmaceutical University of Copenhagen.

Anders Goetzsche

Mr. Anders Goetzsche has been Independent Member of the Board of Directors of Veloxis Pharmaceuticals A/S since April 2008. He is also Chairman of the Audit Committee of the Company. He is Executive Vice President and Chief Financial Officer of H. Lundbeck A/S and Board Member of Rosborg Moebler A/S. He has competencies in Finance. He holds a Master of Science degree in Accounting from Syddansk Universitet from 1991.

Robert Radie

Lars Viksmoen

Paul Wotton